Abstract

Purpose: To compare between first dose of intravitreal ranibizumab and bevacizumab in treatment of ROP in admitted neonates in tertiary care centre jharkhand. Materials and Method: 34 eyes of 17 patients of ROP were examined between October 2022 to September 2023. IVB ( intravitreal bevacizumab)was injected in the left eye and IVR (intravitreal ranibizumab)in the right eye. Post menstrual age( in weeks) of the infants in both IVR and IVB groups at time of intervention were noted Opthalmic examinations were done and all findings noted. Follow up done after 3 weeks and patients were advised for further follow up. Results: Initial regression of ROP within 3 weeks occured in 11/17 in IVB group and 15/17 in IVR group. The need of reinjection occured in 3 out of 17 eyes in IVB group where as no eyes in IVR group. Conclusion: Bevacizumab and ranibizumab proved to be effective regarding regression of acute ROP however higher proportion of reactivation was found with bevacizumab.